Related Experiment Videos
Abstract:
Remifentanil is a new selective mu opioid receptor agonist of higher potency than alfentanil, with pharmacological effects that essentially parallel those of alfentanil and other opioids in this class. Unlike other opioids, remifentanil is rapidly hydrolysed by nonspecific plasma and tissue esterases: this imparts brevity of action, precise and rapidly titratable effects (due to rapid onset and offset), non-cumulative opioid effects and rapid recovery after cessation of administration. The onset of action of remifentanil is similar to that of alfentanil, although its offset is considerably more rapid and independent of the duration of infusion. Remifentanil also has a sparing effect on hypnotics and sedatives. Its brevity of action ensures not only a rapid resolution of adverse effects but also a rapid offset of analgesic effect. Therefore, appropriate postoperative analgesia, when necessary, should be established before discontinuation of remifentanil infusion. The unique pharmacokinetic profile of remifentanil facilitates 'real time' management of intraoperative stress, as well as provision of optimal intraoperative analgesia without compromising recovery for a variety of surgical procedures.
Insights
Remifentanil, a potent mu-opioid agonist, offers rapid onset and offset, enabling precise control during surgery. Its unique metabolism ensures quick recovery, making it ideal for intraoperative analgesia.
Area of Science:
- Anesthesiology and Pharmacology
Background:
- Remifentanil is a novel mu-opioid receptor agonist with high potency.
- Its pharmacological profile is similar to other opioids like alfentanil.
Purpose of the Study:
- To evaluate the unique pharmacokinetic and pharmacodynamic properties of remifentanil.
- To highlight its advantages in intraoperative anesthesia and postoperative pain management.
Main Methods:
- Pharmacokinetic and pharmacodynamic analysis of remifentanil.
- Comparison with existing opioid analgesics.
Main Results:
- Remifentanil is rapidly hydrolyzed by plasma and tissue esterases, leading to short duration of action.
- It provides precise, titratable effects with rapid onset and offset, independent of infusion duration.
- Remifentanil demonstrates non-cumulative effects and allows for rapid patient recovery.
- It also exhibits a sparing effect on hypnotics and sedatives.
Conclusions:
- Remifentanil's unique pharmacokinetic profile allows for real-time management of intraoperative stress.
- Its rapid offset necessitates establishing postoperative analgesia before discontinuation.
- Remifentanil offers optimal intraoperative analgesia without compromising recovery for various surgical procedures.